

AMENDMENT UNDER 37 C.F.R. § 1.111
U.S. Serial No. 09/856,374

4. (Amended) A promoting agent for angiogenesis in the brain comprising, as an active ingredient, an HGF gene and/or a VEGF gene, wherein said HGF gene and said VEGF gene are in the form of HVJ-liposomes.

5. (Amended) A suppressing agent for neuronal death in the brain comprising, as an active ingredient, an HGF gene, wherein said HGF gene is in the form of an HVJ-liposome.

7. (Amended) A suppressing agent for apoptosis of nerve cells in the brain comprising, as an active ingredient, an HGF gene, wherein said HGF gene is in the form of an HVJ-liposome.

8. (Amended) The agent according to any one of claims 1-7 which comprises an HGF gene and/or a VEGF gene as an active ingredient and which is to be used in combination with HGF protein and/or VEGF protein.

9. (Amended) The agent according to claim 8 which comprises an HGF gene as an active ingredient and which is to be used in combination with HGF protein.

13. (Amended) A therapeutic or preventive method for cerebrovascular disorders comprising introducing an HGF gene and/or a VEGF gene into the subarachnoid space in humans.

14. (Amended) A therapeutic or preventive method for reduced blood flow comprising introducing an HGF gene and/or a VEGF gene into the subarachnoid space in humans.

15. (Amended) A method of promoting cerebral angiogenesis comprising introducing an HGF gene and/or a VEGF gene into the subarachnoid space in humans.

16. (Amended) A method of suppressing neuronal death in the brain comprising introducing an HGF gene into the subarachnoid space in humans.

17. (Amended) A method of suppressing apoptosis of nerve cells in the brain comprising introducing an HGF gene into the subarachnoid space in humans.